IL6 and cancer: Microfluidic chip for HTS therapeutic screening in multicellular 3D spheroids. Lenalidomide reduced cancer cells proliferation in 3D spheroids, activated PBMCs and reduced the expression of cytokines associated with a bad prognosis for this type of cancer (IL‐6 and IL‐8, ANG‐1), and increased the secretion of granzyme B.